Skip to contentR
RenovoRx, Inc.
R
RNXTRenovoRx, Inc. Released Mar 29, 2022, after the close
10-K filed Mar 30, 2022, 89 days after period end · 0001493152-22-008080
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.36M-$2.36MderivedN/M vs Q4 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,357,000— Operating Cash Flowderived-$2,558,000N/M ended Dec 31, 2021 · filed Mar 30, 2022 · 89 d after period end
9.1% from the close of Mar 24, 2022 to the close of Mar 31, 2022, the first after the release.
after the close$3.21$2.92 Jan 21Mar 29Jun 9